San Francisco - Topical immunomodulators, specifically imiquimod 5 percent cream (Aldara), may be a viable option for treating patients with invasive squamous cell carcinoma (SCC) or aggressive basal cell carcinoma (BCC) who are no longer candidates for surgery, said Ulrich Hengge, M.D.
